LB Pharmaceuticals, Inc. LBRX 深 沪
已收盘 05-22 16:00:00 美东时间
28.12
+0.120
+0.43%
华盛通- 最 高29.71
- 今 开28.50
- 成交量 14.54万股
- 最 低 27.93
- 昨 收 28.00
- 总市值 8.06亿
- 52周最高 33.47
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 13.36
- 委 比 -18.58%
- 总股本 2867.67万
- 历史最高 33.47
- 量 比 0.73
- 振 幅 6.36%
- 历史最低 13.36
- 每 手 1
- 风险率 5.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 95.47 percent increase over losses of $(14.79) per share
05-13 05:06
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
HC Wainwright & Co. Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $45
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $45.
04-27 19:16
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Craig-Hallum Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $36
Craig-Hallum analyst Adam Vogel initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $36.
04-11 01:54
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $40
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $35 to $40.
03-27 21:47
LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share
03-27 04:30
LB Pharmaceuticals Starts Its Pivotal Phase 3 Study Of LB-102 To Treat Schizophrenia
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder
03-25 20:01
LB Pharmaceuticals Announces Up To $100M Private Offering of 4.72M Shares at $21.17 Each to Fund Clinical Trials
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases,
02-05 21:12
